Numerous studies demonstrate that psychedelic substances are effective in treating various mental health disorders, showing positive results in patients with neurodegenerative or terminal illnesses. This potential is attracting investors, entrepreneurs, biotech startups, and research institutions. The market is evolving towards comprehensive patient care, from drug development and delivery of specialized information to telemedicine applications and community support.

Psilocybin, ketamine, DMT, and 5-MeO-DMT are the most studied molecules, representing two-thirds of active clinical trials. Research particularly focuses on substance use disorders, accounting for 22 percent of these trials. According to IQVIA's report, "Two Steps Forward, One Step Back: The Long Road to Success in CNS," psychedelics are among the most important innovations in central nervous system (CNS) disorders, such as Parkinson's and Alzheimer's diseases. Ongoing studies include psychedelic-based therapies and new-generation biotherapeutics like cell and gene therapies, which hold the potential to reverse or cure neurodegenerative and neuromuscular diseases.

"The international trend towards embracing psychedelic therapies is significant for Poland, which has a wealth of smaller, innovative companies. Increased venture capital investments and patent applications for psychedelics are likely to accelerate industry growth in the coming years," Aleksandra Maciejewicz, a legal expert and HealthTech market analyst, stated.

Global demand for psychedelic-assisted therapies has surged, particularly since the COVID-19 pandemic, with regulators like the FDA and EMA adopting more favorable stances. The U.S. is expected to lead in revenue by 2033, with Asia-Pacific as the fastest-growing region, driven by governmental interest in healthcare infrastructure improvements and the rising prevalence of mental health disorders.

(WBJ)